Synthesis and antifungal activities of novel 2-aminotetralin derivatives

Journal of Medicinal Chemistry

Volumn 50, Issue 22, 2007, Pages 5293-5300

  Yao, Bin ^a   Ji, Haitao ^b   Cao, Yongbin ^a   Zhou, Youjun ^a   Zhu, Jü ^a   Lü, Jiaguo ^a   Li, Yaowu ^a   Chen, Jun ^a   Zheng, Canhui ^a   Jiang, Yuanying ^a   Liang, Rongmei ^a   Tang, Hui ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 ALPHA DEMETHYLASE; 2 AMINOTETRALIN DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; STEROL 14ALPHA DEMETHYLASE; TERBINAFINE; TETRAHYDROISOQUINOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGAL STRAIN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; VAGINA CANDIDIASIS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIFUNGAL AGENTS; BINDING SITES; CANDIDA ALBICANS; CANDIDIASIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; OXIDOREDUCTASES; PROTEIN BINDING; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES; VAGINAL DISEASES;

EID: 35848965284     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0701167     Document Type: Article

References (52)

1. Nina, S. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis. 2001, 33, 1692-1696.
2. Fridkin, S. K.; Jarvis, W. R. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 1996, 9, 499-511.
3. Ablordeppey, S. Y.; Fan, P.; Ablordeppey, J. H.; Mardenborough, L. Systemic antifungal agents against AIDS-related opportunistic infections: Current status and emerging drugs in development. Curr. Med. Chem. 1999, 6, 1151-1196.
4. Beck-Sague, C. M.; Jarvis, W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 1993, 167, 1247-1251.
5. Wildfeuer, A.; Seidl, H. P.; Paule, I.; Haberreiter, A. In vitro evaluation of voriconazole against clinical isolates of yeast, moulds, and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin and griseofulvin. Mycoses 1998, 41, 306-319.
6. Georgopapadakou, N. H. Antifungals: Mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1998, I, 547-557.
7. Hartman, P. G.; Sanglard, D. Inhibitors of ergosterol biosynthesis as antifungal agents. Curr. Pharm. Des. 1997, 3, 177-208.
8. Brajtburg, J.; Powderly, W. G.; Kobayashi, G. S.; Medoff, G. Amphotericin B: Current understanding of mechanisms of action. Antimicrob. Agents Chemother. 1990, 34, 183-188.
9. Morrison, V. A. Echiniocandin antifungals: Review and update. Expert Rev. Anti. Infect. Ther. 2006, 4(2), 325-342.
10. Kurtz, M. B.; Rex, J. H. Glucan synthase inhibitors as antifungal agents. Adv. Protein Chem. 2001, 56, 423-475.
11. Maertens, J. A. History of the development of azole derivatives. Clin. Microbiol. Infec. 2004, 10 (Suppl. I), 1-10.
12. Stütz, A. Allylamine derivatives - A new class of active substances in antifungal chemotherapy. Angew. Chem., Int. Ed. Engl. 1987, 26, 320-328.
13. 14 reductase by fenpropimorph, tridemorph, and fenpropidin in cell-free systems from Saccharomyces cerevisiae. Phytochemistry 1987, 26, 663-668.
14. Sheehan, D. J.; Hitchcock, C. A.; Sibley, C. M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999, 12, 40-79.
15. Marichal, P. Mechanisms of resistance to azole antifungal compounds. Curr. Opin. Anti-Infect. Invest. Drugs 1999, 1, 318-333.
16. Kale, P.; Johnson, L. B. Second-generation azole antifungal agents. Drugs Today 2005, 41, 91-105.
17. William, E. D. Introduction to antifungal drugs. Clin. Infect. Dis. 2000, 30, 653-657.
18. Koltin, Y. Target for antifungal drug discovery. Annu. Rep. Med. Chem. 1990, 25, 141-148.
19. Fromtling, R. A. Imidazoles as medically important antifungal agents: An overview. Drugs Today 1986, 20, 235-349.
20. Aperis, G.; Mylonakis, E. Newer triazole antifungal agents: Pharmacology, spectrum, clinical efficacy, and limitations. Expert Opin. Invest. Drugs 2006, 15, 579-602.
21. Hitchcock, C. A.; Dickinson, K.; Brown, S. B.; Evans, E. G. V.; Adams, D. J. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14α-sterol demethylase purified from Candida albicans. Biochem. J. 1990, 266, 475-480.
22. Slama, J. T.; Hancock, J. L.; Rho, T.; Sambucetti, L.; Bachmann, K. A. Influence of some novel N-substituted azole and pyridines on rat hepatic CYP3A activity. Biochem. Pharmacol. 1998, 55, 1881-1892.
23. + channel, IK-Cal: A potential immuno suppressant. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8151-8156.
24. Somchit, N.; Norshahida, A. R.; Hasiah, A. H.; Zuraini, A.; Sulaiman, M. R.; Noordin, M. M. Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study. Hum. Exp. Toxicol. 2004, 23, 519-525.
25. Adriaenssens, B.; Roskams, T.; Steger, P.; Van Steenbergen, W. Hepatotoxicity related to itraconazole: report of three cases. Acta Clin. Belg. 2001, 56, 364-369.
26. Rodriguez, R. J.; Buckholz, C. J. Hepatotoxicity of ketoconazole in Sprague-Dawley rats: Glutathione depletion, flavin-containing monooxy-genases-mediated bioactivation and hepatic covalent binding. Xenobiotica 2003, 33, 429-441.
27. Ma, Y. M.; Ma, Z. Q.; Gui, C. Q.; Yao, J. S.; Sun, R. Y. Hepatotoxicity and toxicokinetics of ketoconazole in rabbits. Acta Pharmacol. Sin. 2003, 24, 778-782.
28. Bok, R. A.; Small, E. J. The treatment of advanced prostate cancer with ketoconazole: Safety issues. Drug Safety 1999, 20, 451-458.
29. Nair, D. R.; Morris, H. H. Potential fluconazole-induced carbamazepine toxicity. Ann. Pharmacother. 1999, 33, 790-792.
30. Jeng, M. R.; Feusner, J. ltraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 2001, 18, 137-142.
31. Wolf, R.; Wolf, D.; Kuperman, S. Focal nodular hyperplasia of the liver after intraconazole treatment. J. Clin. Gastroenterol. 2001, 33, 418-420.
32. Kauffman, C. A.; Hedderwick, S. A. Treatment of systemic fungal Infections in older patients: Achieving optimal outcomes. Drugs Aging 2001, 18, 313-323.
33. Su, F. W.; Perumalswami, P.; Grammer, L. C. Acute hepatitis and rash to fluconazole. Allergy 2003, 58, 1215-1216.
34. Linnebur, S. A.; Parnes, B. L. Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment. Ann. Pharmacother. 2004, 38, 612-616.
35. Legras, A.; Bergemer-Fouguet, A. M.; Jonville-Bera, A. P. Fatal hepatitis with leflunomide and itraconazole. Am. J. Med. 2002, 113, 352-353.
36. Plempel, M. Experience, recognitions, and questions in azole antimycotics. Shinkin to Shinkinsho 1982, 23, 17-27.
37. Fromtling, R. A. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1988, 1, 187-217.
38. Ji, H.; Zhang, W.; Zhang, M.; Kudo, M.; Aoyama, Y.; Yoshida, Y.; Sheng, C.; Song, Y.; Yang, S.; Zhou, Y.; Lu, J.; Zhu, J. Structure based de novo design, synthesis, and biolpgical evaluation of nonazole inhibitors specific for lanosterol 14α-demethylase of fungi. J. Med. Chem. 2003, 46, 474-485.
39. Zhu, J.; Lu, J.; Zhou, Y.; Li, Y.; Cheng, J.; Zheng, C. Design, synthesis, and antifungal acivities in vitro of novel tetrahydroisoquinoline compounds based on the structure of lanosterol demethylase (CYP51) of fungi. Bioorg. Med. Chem. Lett. 2006, 16, 5285-5289.
40. Ji, H.; Zhang, W.; Zhou, Y.; Zhang, M.; Zhu, J.; Song, Y.; Lü, J.; Zhu, J. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J. Med. Chem. 2000, 43, 2493-2505.
41. Sheng, C.; Zhang, W.; Zhang, M.; Song, Y.; Ji, H.; Zhu, J.; Yao, J.; Yu, J.; Yang, S.; Zhou, Y.; Zhu, J.; Lu, J. Homology modeling of lanosterol 14α-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate interactions. J. Biomol. Struct. Dyn. 2004, 22, 91-99.
42. Cornforth, J. W.; Cornforth, R H.; Robinson, R. The preparation of β-tetralone from β-naphthol and some analogous transformations. J. Chem. Soc. 1942, 689-691.
43. Ames, D. E.; Evans, D.; Grey, T. F.; Islip, P. J.; Richards, K. E. The synthesis of alkoxy-1,2,3,4-tetrahydronaphthalene derivatives. Part I. 2-Amino-, alkylamiio-, and dialkyl-amino-derivatives. J. Chem. Soc. 1965, 2636-2641.
44. Cornforth, J. W.: Robinson, R. Experiments on the synthesis of substances related to the sterols. Part XLVIII. Synthesis of a tricyclic degradation product of cholesterol. J. Chem. Soc. 1949, 1855-1865.
45. Soffer, M. D.; Cavagnol, J. C.; Gellerson, H. E. Syntheses in the direction of morphine. I. 7-Methoxy and 7,8-dimefhoxy-2-tetralone. J. Am. Chem. Soc. 1949, 71, 3857-3857.
46. Robins, P. A.; Walker, J. A new and specific aromatisation reaction. Part [squlo] Aromatisation of isolated 1,4-dioxocyclohexaue rings. J. Chem. Soc. 1958, 409-421.
47. Hacksell, U.; Svensson, U.; Nilsson, J. L. G.; Hjorth, 5.; Carlsson, A.; WiketrÖm, H.; Lindberg, P.; Sanchez, D. N-Alkylated 2-aminotetralins; central dopamine-receptor stimulating activity. J. Med. Chem. 1979, 22, 1469-1475.
48. InsightII 2000; Molecular Simulation, Inc.: 9685 Scranton Road, San Diego, CA 92121-3752, 1999.
49. Luty, B. A.; Wasserman, Z. R.; Stouten, P. F. W.; Hodge, C. N.; Zacharias, M.; McCammon, J. A. A molecular mechanics/grid method for evalution of ligand-receptor interactions. J. Comput. Chem. 1995, 16, 454-464.
50. Böhm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
51. Böhm, H. J. Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput.-Aided Mol. Des. 1998, 12, 309-323.
52. Chami, F.; Chami, N.; Bennis, S.; Trouillas, J.; Remmal, A. Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model. J. Antimicrob. Chemother. 2004, 54, 909-914.